BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 17873385)

  • 1. Stem cell origin of death-from-cancer phenotypes of human prostate and breast cancers.
    Glinsky GV
    Stem Cell Rev; 2007 Jan; 3(1):79-93. PubMed ID: 17873385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management.
    Glinsky GV
    J Clin Oncol; 2008 Jun; 26(17):2846-53. PubMed ID: 18539963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors.
    Glinsky GV
    Cancer Lett; 2016 Oct; 381(1):176-93. PubMed ID: 27497790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
    Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
    Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A basal stem cell signature identifies aggressive prostate cancer phenotypes.
    Smith BA; Sokolov A; Uzunangelov V; Baertsch R; Newton Y; Graim K; Mathis C; Cheng D; Stuart JM; Witte ON
    Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6544-52. PubMed ID: 26460041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Networks of intergenic long-range enhancers and snpRNAs drive castration-resistant phenotype of prostate cancer and contribute to pathogenesis of multiple common human disorders.
    Glinskii AB; Ma S; Ma J; Grant D; Lim CU; Guest I; Sell S; Buttyan R; Glinsky GV
    Cell Cycle; 2011 Oct; 10(20):3571-97. PubMed ID: 22067658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival.
    Chen Y; Sadasivan SM; She R; Datta I; Taneja K; Chitale D; Gupta N; Davis MB; Newman LA; Rogers CG; Paris PL; Li J; Rybicki BA; Levin AM
    BMC Med Genomics; 2020 Aug; 13(1):116. PubMed ID: 32819446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.
    Deeb KK; Michalowska AM; Yoon CY; Krummey SM; Hoenerhoff MJ; Kavanaugh C; Li MC; Demayo FJ; Linnoila I; Deng CX; Lee EY; Medina D; Shih JH; Green JE
    Cancer Res; 2007 Sep; 67(17):8065-80. PubMed ID: 17804718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.
    Yu J; Yu J; Rhodes DR; Tomlins SA; Cao X; Chen G; Mehra R; Wang X; Ghosh D; Shah RB; Varambally S; Pienta KJ; Chinnaiyan AM
    Cancer Res; 2007 Nov; 67(22):10657-63. PubMed ID: 18006806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics.
    Martinez-Outschoorn UE; Prisco M; Ertel A; Tsirigos A; Lin Z; Pavlides S; Wang C; Flomenberg N; Knudsen ES; Howell A; Pestell RG; Sotgia F; Lisanti MP
    Cell Cycle; 2011 Apr; 10(8):1271-86. PubMed ID: 21512313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.
    Kunderfranco P; Mello-Grand M; Cangemi R; Pellini S; Mensah A; Albertini V; Malek A; Chiorino G; Catapano CV; Carbone GM
    PLoS One; 2010 May; 5(5):e10547. PubMed ID: 20479932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of activated enhancers and linked transcription factors in breast, prostate, and kidney tumors by tracing enhancer networks using epigenetic traits.
    Rhie SK; Guo Y; Tak YG; Yao L; Shen H; Coetzee GA; Laird PW; Farnham PJ
    Epigenetics Chromatin; 2016; 9():50. PubMed ID: 27833659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of endogenous human stem cell-associated retroviruses (SCARs) and therapy-resistant phenotypes of malignant tumors.
    Glinsky GV
    Cancer Lett; 2016 Jul; 376(2):347-59. PubMed ID: 27084523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing PRDM14 expression by an innovative RNAi therapy inhibits stemness, tumorigenicity, and metastasis of breast cancer.
    Taniguchi H; Hoshino D; Moriya C; Zembutsu H; Nishiyama N; Yamamoto H; Kataoka K; Imai K
    Oncotarget; 2017 Jul; 8(29):46856-46874. PubMed ID: 28423353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.
    Paranjape AN; Balaji SA; Mandal T; Krushik EV; Nagaraj P; Mukherjee G; Rangarajan A
    BMC Cancer; 2014 Oct; 14():785. PubMed ID: 25348805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative analysis reveals disrupted pathways regulated by microRNAs in cancer.
    Wilk G; Braun R
    Nucleic Acids Res; 2018 Feb; 46(3):1089-1101. PubMed ID: 29294105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of HapMap-based SNP pattern analysis and gene expression profiling reveals common SNP profiles for cancer therapy outcome predictor genes.
    Glinsky GV
    Cell Cycle; 2006 Nov; 5(22):2613-25. PubMed ID: 17172834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomics-Guided Drawing of Molecular and Pathophysiological Components of Malignant Regulatory Signatures Reveals a Pivotal Role in Human Diseases of Stem Cell-Associated Retroviral Sequences and Functionally-Active hESC Enhancers.
    Glinsky GV
    Front Oncol; 2021; 11():638363. PubMed ID: 33869024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The polycomb group protein EZH2 is involved in progression of prostate cancer.
    Varambally S; Dhanasekaran SM; Zhou M; Barrette TR; Kumar-Sinha C; Sanda MG; Ghosh D; Pienta KJ; Sewalt RG; Otte AP; Rubin MA; Chinnaiyan AM
    Nature; 2002 Oct; 419(6907):624-9. PubMed ID: 12374981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of embryonal stem cell transcription factors in breast cancer: Oct4 as an indicator for poor clinical outcome and tamoxifen resistance.
    Gwak JM; Kim M; Kim HJ; Jang MH; Park SY
    Oncotarget; 2017 May; 8(22):36305-36318. PubMed ID: 28422735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.